The detailed results from the HARMONi trial—the first global phase 3 data set for the world’s first PD-1xVEGF bispecific, ...

Explore the importance of robust statistics like median and MAD in data analysis, ensuring accurate insights despite outliers ...

Revolution Medicines, Inc. shares surged on strong Phase 1 data for daraxonrasib in metastatic pancreatic cancer. Click here ...

Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO ® (osimertinib) with the addition of pemetrexed and platinum-based ...

Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George ...

Tom Nolan reviews this week’s research Aspirin is the first choice antiplatelet therapy for people with stable coronary heart disease. However, an individual patient data meta-analysis of seven ...

Chemotherapy-free combination regimen has the potential to usher in new era for first-line treatment, with median overall survival projected to exceed four years, surpassing monotherapy TKI osimertini ...

Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces ...

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SoFi, a leading provider of thematic and income ETFs, today announced monthly distributions on the SoFi Enhanced Yield ETF (THTA). Inception date: ...

In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability ...